Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Kailera Therapeutics, Inc. (KLRA)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Kailera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Hemab Therapeutics Holdings, Inc. Common Stock logo
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$1.35B
$28.94HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Kailera Therapeutics, Inc. logo
KLRA
Kailera Therapeutics, Inc.
$1.40B
$10.84HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT

Total return — COAG vs KLRA

growth of $100 · dividends reinvested · last 1y
COAG -10.0% (-10.0%/yr)KLRA -56.9% (-56.9%/yr)COAG compounded faster over this window
50100150Start $100$90$43
COAG KLRA

COAG vs KLRA: by the numbers

  • •KLRA is the larger company ($1.40B vs $1.35B market cap).

Metrics side by side

Valuation

MetricCOAGKLRA
P/B ratio2.981.26

Profitability

MetricCOAGKLRA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROIC-38.09%-24.52%

Go deeper

Full COAG analysisFull KLRA analysisInteractive comparison tool

Dig into the metrics

Hemab Therapeutics Holdings, Inc. Common Stock ROEKailera Therapeutics ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginKailera Therapeutics operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthKailera Therapeutics revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowKailera Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.